Cargando…

Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial

BACKGROUND: For immunocompromised patients (ICPs), administration of rabies immunoglobulins (RIG) after exposure is still recommended regardless of prior vaccination, due to a lack of data. We aimed to assess the 1-year boostability of a three-dose rabies pre-exposure prophylaxis (PrEP) schedule in...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia Garrido, Hannah M, van Put, Bridget, Terryn, Sanne, de Pijper, Cornelis A, Stijnis, Cornelis, D’Haens, Geert R, Spuls, Phyllis I, van de Sande, Marleen G, van Gucht, Steven, Grobusch, Martin P, Goorhuis, Abraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075057/
https://www.ncbi.nlm.nih.gov/pubmed/36477981
http://dx.doi.org/10.1093/jtm/taac148
_version_ 1785019842770763776
author Garcia Garrido, Hannah M
van Put, Bridget
Terryn, Sanne
de Pijper, Cornelis A
Stijnis, Cornelis
D’Haens, Geert R
Spuls, Phyllis I
van de Sande, Marleen G
van Gucht, Steven
Grobusch, Martin P
Goorhuis, Abraham
author_facet Garcia Garrido, Hannah M
van Put, Bridget
Terryn, Sanne
de Pijper, Cornelis A
Stijnis, Cornelis
D’Haens, Geert R
Spuls, Phyllis I
van de Sande, Marleen G
van Gucht, Steven
Grobusch, Martin P
Goorhuis, Abraham
author_sort Garcia Garrido, Hannah M
collection PubMed
description BACKGROUND: For immunocompromised patients (ICPs), administration of rabies immunoglobulins (RIG) after exposure is still recommended regardless of prior vaccination, due to a lack of data. We aimed to assess the 1-year boostability of a three-dose rabies pre-exposure prophylaxis (PrEP) schedule in individuals using immunosuppressive monotherapy. METHODS: In this prospective study, individuals on immunosuppressive monotherapy with a conventional immunomodulator (cIM) or a TNF-alpha inhibitor (TNFi) for a chronic inflammatory disease received a three-dose intramuscular PrEP schedule (days 0,7,21–28) with 1 mL Rabipur®, followed by a two-dose simulated post-exposure prophylaxis (PEP) schedule (days 0,3) after 12 months. Rabies neutralizing antibodies were assessed at baseline, on day 21–28 (before the third PrEP dose), day 60, month 12 and month 12 + 7 days. The primary outcome was 1-year boostability, defined as the proportion of patients with a neutralizing antibody titre of ≥ 0.5 IU/mL at month 12 + 7 days. Secondary outcomes were geometric mean titres (GMTs) and factors associated with the primary endpoint. RESULTS: We included 56 individuals, of whom 52 completed the study. The 1-year boostability was 90% (47/52) with a GMT of 6.16 (95% CI 3.83–9.91). All participants seroconverted at some point in the study. Early response to PrEP (at day 21–28) was significantly associated with 100% boostability (Odds Ratio 51; 95% confidence interval [5.0–6956], P < 0.01). The vaccination schedule was safe and well tolerated. No vaccine-related serious adverse events occurred. CONCLUSION: In patients using immunosuppressive monotherapy, a three-dose rabies PrEP schedule followed by a two-dose PEP schedule is immunogenic, with all patients seroconverting at some point in the study. Although boostability 7 days after PEP was not 100%, nobody would wrongly be denied RIG when only administered to those who responded early to PrEP while reducing the administration of RIG by 73%.
format Online
Article
Text
id pubmed-10075057
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-100750572023-04-06 Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial Garcia Garrido, Hannah M van Put, Bridget Terryn, Sanne de Pijper, Cornelis A Stijnis, Cornelis D’Haens, Geert R Spuls, Phyllis I van de Sande, Marleen G van Gucht, Steven Grobusch, Martin P Goorhuis, Abraham J Travel Med Original Article BACKGROUND: For immunocompromised patients (ICPs), administration of rabies immunoglobulins (RIG) after exposure is still recommended regardless of prior vaccination, due to a lack of data. We aimed to assess the 1-year boostability of a three-dose rabies pre-exposure prophylaxis (PrEP) schedule in individuals using immunosuppressive monotherapy. METHODS: In this prospective study, individuals on immunosuppressive monotherapy with a conventional immunomodulator (cIM) or a TNF-alpha inhibitor (TNFi) for a chronic inflammatory disease received a three-dose intramuscular PrEP schedule (days 0,7,21–28) with 1 mL Rabipur®, followed by a two-dose simulated post-exposure prophylaxis (PEP) schedule (days 0,3) after 12 months. Rabies neutralizing antibodies were assessed at baseline, on day 21–28 (before the third PrEP dose), day 60, month 12 and month 12 + 7 days. The primary outcome was 1-year boostability, defined as the proportion of patients with a neutralizing antibody titre of ≥ 0.5 IU/mL at month 12 + 7 days. Secondary outcomes were geometric mean titres (GMTs) and factors associated with the primary endpoint. RESULTS: We included 56 individuals, of whom 52 completed the study. The 1-year boostability was 90% (47/52) with a GMT of 6.16 (95% CI 3.83–9.91). All participants seroconverted at some point in the study. Early response to PrEP (at day 21–28) was significantly associated with 100% boostability (Odds Ratio 51; 95% confidence interval [5.0–6956], P < 0.01). The vaccination schedule was safe and well tolerated. No vaccine-related serious adverse events occurred. CONCLUSION: In patients using immunosuppressive monotherapy, a three-dose rabies PrEP schedule followed by a two-dose PEP schedule is immunogenic, with all patients seroconverting at some point in the study. Although boostability 7 days after PEP was not 100%, nobody would wrongly be denied RIG when only administered to those who responded early to PrEP while reducing the administration of RIG by 73%. Oxford University Press 2022-12-08 /pmc/articles/PMC10075057/ /pubmed/36477981 http://dx.doi.org/10.1093/jtm/taac148 Text en © International Society of Travel Medicine 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Garcia Garrido, Hannah M
van Put, Bridget
Terryn, Sanne
de Pijper, Cornelis A
Stijnis, Cornelis
D’Haens, Geert R
Spuls, Phyllis I
van de Sande, Marleen G
van Gucht, Steven
Grobusch, Martin P
Goorhuis, Abraham
Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial
title Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial
title_full Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial
title_fullStr Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial
title_full_unstemmed Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial
title_short Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial
title_sort immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075057/
https://www.ncbi.nlm.nih.gov/pubmed/36477981
http://dx.doi.org/10.1093/jtm/taac148
work_keys_str_mv AT garciagarridohannahm immunogenicityand1yearboostabilityofathreedoseintramuscularrabiespreexposureprophylaxisscheduleinadultsreceivingimmunosuppressivemonotherapyaprospectivesinglecentreclinicaltrial
AT vanputbridget immunogenicityand1yearboostabilityofathreedoseintramuscularrabiespreexposureprophylaxisscheduleinadultsreceivingimmunosuppressivemonotherapyaprospectivesinglecentreclinicaltrial
AT terrynsanne immunogenicityand1yearboostabilityofathreedoseintramuscularrabiespreexposureprophylaxisscheduleinadultsreceivingimmunosuppressivemonotherapyaprospectivesinglecentreclinicaltrial
AT depijpercornelisa immunogenicityand1yearboostabilityofathreedoseintramuscularrabiespreexposureprophylaxisscheduleinadultsreceivingimmunosuppressivemonotherapyaprospectivesinglecentreclinicaltrial
AT stijniscornelis immunogenicityand1yearboostabilityofathreedoseintramuscularrabiespreexposureprophylaxisscheduleinadultsreceivingimmunosuppressivemonotherapyaprospectivesinglecentreclinicaltrial
AT dhaensgeertr immunogenicityand1yearboostabilityofathreedoseintramuscularrabiespreexposureprophylaxisscheduleinadultsreceivingimmunosuppressivemonotherapyaprospectivesinglecentreclinicaltrial
AT spulsphyllisi immunogenicityand1yearboostabilityofathreedoseintramuscularrabiespreexposureprophylaxisscheduleinadultsreceivingimmunosuppressivemonotherapyaprospectivesinglecentreclinicaltrial
AT vandesandemarleeng immunogenicityand1yearboostabilityofathreedoseintramuscularrabiespreexposureprophylaxisscheduleinadultsreceivingimmunosuppressivemonotherapyaprospectivesinglecentreclinicaltrial
AT vanguchtsteven immunogenicityand1yearboostabilityofathreedoseintramuscularrabiespreexposureprophylaxisscheduleinadultsreceivingimmunosuppressivemonotherapyaprospectivesinglecentreclinicaltrial
AT grobuschmartinp immunogenicityand1yearboostabilityofathreedoseintramuscularrabiespreexposureprophylaxisscheduleinadultsreceivingimmunosuppressivemonotherapyaprospectivesinglecentreclinicaltrial
AT goorhuisabraham immunogenicityand1yearboostabilityofathreedoseintramuscularrabiespreexposureprophylaxisscheduleinadultsreceivingimmunosuppressivemonotherapyaprospectivesinglecentreclinicaltrial